Defence Therapeutics Inc.
DTCFF
$0.66
$0.047.21%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.79M | 1.70M | 2.47M | 2.25M | 6.57M |
| Depreciation & Amortization | 50.70K | 51.90K | 73.50K | 77.90K | 70.30K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.41M | 2.33M | 3.31M | 3.49M | 8.80M |
| Operating Income | -2.41M | -2.33M | -3.31M | -3.49M | -8.80M |
| Income Before Tax | -2.59M | -2.52M | -2.67M | -2.99M | -8.53M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.59 | -2.52 | -2.67 | -2.99 | -8.53 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.59M | -2.52M | -2.67M | -2.99M | -8.53M |
| EBIT | -2.41M | -2.33M | -3.31M | -3.49M | -8.80M |
| EBITDA | -2.38M | -2.29M | -3.26M | -3.44M | -8.75M |
| EPS Basic | -0.05 | -0.05 | -0.06 | -0.07 | -0.19 |
| Normalized Basic EPS | -0.03 | -0.03 | -0.04 | -0.04 | -0.12 |
| EPS Diluted | -0.05 | -0.05 | -0.06 | -0.07 | -0.19 |
| Normalized Diluted EPS | -0.03 | -0.03 | -0.04 | -0.04 | -0.12 |
| Average Basic Shares Outstanding | 204.84M | 195.65M | 186.45M | 181.85M | 179.75M |
| Average Diluted Shares Outstanding | 204.84M | 195.65M | 186.45M | 181.85M | 179.75M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |